|
|
 |
| |
|
Home > Weight Loss News > Research Supporting Compellis Pharmaceuticals’ Weight Loss Drug Therapy
Research Supporting Compellis Pharmaceuticals’ Weight Loss Drug Therapy
Boston, MA (PRWEB) December 21, 2005 -- Compellis Pharmaceuticals, an early-stage specialty pharmaceutical company focused on developing therapeutics that treat obesity and related disorders, such as diabetes and hypertension, announced today that scientists at the Massachusetts College of Pharmacy have published research findings in Pharmacology, Biochemistry and Behavior that support the company’s therapeutic approach to obesity. Compellis Pharmaceuticals has developed an obesity therapy that is based on blocking olfactory sensory perception to reduce appetite and cause people to eat less.
The study titled “Nasal Administration of the Calcium Channel Blocker Diltiazem Decreases Food Intake and Attenuates Weight Gain in Rats,” was conducted by Ahmed Amer and Timothy J. Maher from the Massachusetts College of Pharmacy. In the study, the Compellis drug was introduced into the nasal passageways of rats targeting the calcium channels of the olfactory epithelium. The scientists found that the rats given the drug had a decreased capacity to smell and ate significantly less than the rats that were given the placebo. In the feeding study, the rats on the drug showed a 20 percent reduction in weight gain over a 14-day period. Once the drug was removed, no adverse effects on normal growth were found.
“Obese patients often describe an uncontrollable urge to eat foods triggered by the appealing aromas of food,” said Christopher P. Adams, founder and CEO of Compellis Pharmaceuticals. “This study clearly shows that by taking away the appealing aromas of food in the earliest stages of olfactory perception reduces appetite and causes people to reduce their food intake. Compellis has developed a therapy that satisfies the critical need for better drugs that intervene in the processes of obesity and related disorders such as diabetes and hypertension. It is a non-invasive therapy that will make a dramatic impact on the treatment of obesity.”
Obesity is caused by many factors and includes the lack of control of feeding behavior, mechanisms of fat storage, components of energy intake and expenditure, and genetic and psychological influences. The treatment regimen for reversing obesity is generally a complex process. Targeting the mechanisms of lipid metabolism and fat storage or understanding genetic influences have not provided adequate results. Controlling energy food intake by suppressing appetite has shown to be an effective approach for the treatment of obesity.
About Compellis Pharmaceuticals, Inc.
Compellis Pharmaceuticals is an early-stage specialty pharmaceutical company focused on developing therapeutics that treat obesity and related disorders, such as diabetes and hypertension. The company reformulates FDA approved products and identifies proprietary delivery methods to treat broad metabolic disorders.
Back to Weight Loss News
|
|
|
|
|
|
|